Enquiries to Ministry of Health 0800 855 066

## APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 1 Form SA2550 December 2025

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:
Reg No:	First Names:	First Names:
Name:	Surname:	Surname:
Address:	DOB:	Address:
	Address:	
Fax Number:		Fax Number:
Aflibercept		
and Patient has reduced visual acuity be and Patient has DMO within central OC and There is no centre-involving sub-ret and	c macular oedema (DMO)  to 4 doses of intravitreal bevacizumab when admini etween 6/9 – 6/36 with functional awareness of reduced to the control of the cont	ction in vision
Renewal — diabetic macular oedema  Current approval Number (if known):	als valid for 12 months.  ellen visual acuity gain  OCT scan (with reduction in intra-retinal cysts, centre the Snellen visual acuity score	ral retinal thickness, and sub-retinal fluid)

I confirm the above details are correct and that in signing this form I understand I may be audited.

Enquiries to Ministry of Health 0800 855 066

## APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 2 Form SA2550 December 2025

APPLICANT (stamp or sticker acceptable)			np c	r sticker acceptable)	PATIENT NHI:	REFERRER Reg No:		
Reg No:					First Names:	First Names:		
Name:					Surname:	Surname:		
Address:					DOB:	Address:		
					Address:			
Fax Number:						Fax Number:		
Aflib	erce	<b>pt</b> - <i>c</i>	onti	nued				
Initial application — wet age related macular degeneration Applications from any relevant practitioner. Approvals valid for 3 months.  Prerequisites(tick boxes where appropriate)								
	or	and and and	or or	Polypoidal choroidal value Choroidal neovascular Choroidal neovascular The patient has devel apart There is worsening of apart There is no structural damage. Patient has not previously be Patient has current approva 3 months	ular degeneration (wet AMD)  vasculopathy  ir membrane from causes other than wet AMD  oped severe endophthalmitis or severe posterior uveir  i vision or failure of retina to dry despite three intraocul  ge to the central fovea of the treated eye  een treated with ranibizumab or faricimab for longer the second of the treatment of walk  I to use ranibizumab or faricimab for treatment of walk  fore June 2018) received treatment with ranibizumab	han 3 months  MD and was found to be intolerant within		
Renewal — wet age related macular degeneration  Current approval Number (if known):								
	and	Documented benefit must be demonstrated to continue  Patient's vision is 6/36 or better on the Snellen visual acuity score						
	There is no structural damage to the central fovea of the treated eye							